<DOC>
	<DOCNO>NCT00437918</DOCNO>
	<brief_summary>In type 2 diabetic patient , tight blood glucose control often require fast post-prandial glucose control separately . In diabetic patient already insulin glargine treatment control fast blood glucose , additional measure control post-prandial glucose level often require . Nateglinide acarbose frequently use purpose . We hypothesize short act sulfonylurea `` nateglinide '' may efficacious diabetic patient appreciable endogenous insulin secretion , acarbose may efficacious patient low endogenous insulin secretion . And also want clarify clinical biochemical parameter predict responsiveness agent multi-center randomize open cross-over clinical study .</brief_summary>
	<brief_title>The Effects Nateglinide Acarbose Post-Prandial Glucose Control Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<criteria>Korean Type 2 diabetes mellitus No prior history diabetic ketoacidosis HbA1c 7.510.0 % Type 1 diabetes mellitus Gestational diabetes mellitus Secondary diabetes mellitus Severe hyperglycemia symptom Severe chronic diabetic complication ( PDR , sCr &gt; 1.3mg/dL )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>